Nkarta, Inc. (NKTX)

NASDAQ: NKTX · Delayed Price · USD
12.14
-0.10 (-0.82%)
At close: Jan 14, 2022 4:00 PM
12.25
0.11 (0.91%)
After-hours:Jan 14, 2022 7:47 PM EST

Company Description

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment.

The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.

Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells.

The company was incorporated in 2015 and is based in South San Francisco, California.

Nkarta, Inc.
CountryUnited States
Founded2015
IPO DateJul 10, 2020
IndustryBiotechnology
SectorHealth Care
Employees133

Contact Details

Address:
6000 Shoreline Court
South San Francisco, CA 94080
United States
Phone415 582 4923
Websitenkartatx.com

Stock Details

Ticker SymbolNKTX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$18.00
CIK Code1787400

Key Executives

NamePosition
Paul J. HastingsChief Executive Officer, President and Director
Dr. Nadir Mahmood Ph.D.Chief Financial and Business Officer
Dr. Alicia J. HagerChief Legal Officer and Corporate Secretary
Dr. Ralph Brandenberger Ph.D.Senior Vice President of Technical Operations
Dr. James Trager Ph.D., Ph.D.Chief Scientific Officer
Greg MannVice President of Public Affairs and Investor Relations
Dr. Kanya RajangamChief Medical Officer

Latest SEC Filings

DateTypeTitle
Dec 3, 20214Statement of changes in beneficial ownership of securities
Nov 22, 2021SC 13D/AGeneral statement of acquisition of beneficial ownership
Nov 10, 202110-QQuarterly report [Sections 13 or 15(d)]
Nov 10, 20218-KCurrent report
Oct 22, 20218-KCurrent report
Oct 7, 20218-KCurrent report
Oct 1, 20214Statement of changes in beneficial ownership of securities
Sep 2, 2021424B5Prospectus [Rule 424(b)(5)]
Sep 3, 2021EFFECTNotice of Effectiveness
Sep 2, 20214Statement of changes in beneficial ownership of securities
View All SEC Filings